Cancer patients carrying RAS mutations—affecting one in five diagnoses—may soon benefit from dramatically expanded treatment options that move beyond the limitations of current targeted therapies. The breakthrough represents a potential shift from treating a narrow subset of patients to addressing the broader population of RAS-driven cancers that have historically proven nearly impossible to target effectively. Current KRASG12C inhibitors like sotorasib and adagrasib marked the first successful direct assault on this notorious "undruggable" protein family, but their clinical impact remains constrained by rapid resistance development and coverage of only the G12C mutation variant. These first-generation drugs demonstrate meaningful but temporary responses, with most patients experiencing disease progression within months as cancer cells adapt through various bypass mechanisms. The emerging therapeutic pipeline addresses these shortcomings through multiple innovative approaches: pan-RAS inhibitors designed to block multiple mutation variants simultaneously, next-generation G12C compounds with improved resistance profiles, and novel agents targeting alternative RAS variants like G12D and G12V that collectively affect far more patients than G12C alone. Several experimental classes employ fundamentally different mechanisms, including protein degraders that eliminate RAS proteins entirely and combination strategies that prevent common resistance pathways. This therapeutic evolution could transform outcomes for lung, colorectal, and pancreatic cancers where RAS mutations drive some of the most aggressive disease courses. The clinical challenge lies in determining optimal sequencing and combination strategies while managing the increased toxicity risks that broader RAS inhibition may introduce across normal cellular processes.